Related by context. All words. (Click for frequent words.) 67 immune modulating 66 preclinically 66 Onconase 65 immunotoxin 65 orally dosed 65 JAK2 inhibitor 65 YONDELIS 65 therapeutic monoclonal antibody 65 histone deacetylase inhibitor 64 humanised monoclonal antibody 64 antibody MAb 64 Monoclonal antibody 64 novel peptide 64 Src inhibitors 64 HQK 64 Temsirolimus 64 HGS# 64 bortezomib Velcade 64 predictive biomarkers 63 CBLC# 63 Squalamine 63 PROCHYMAL 63 gamma secretase inhibitors 63 peptide conjugated 63 Insegia 63 Valproic acid 63 HepDirect prodrug 63 BrachySil TM 63 IAP inhibitors 63 SGLT2 inhibitors 63 PEGylated interferon 63 Kahalalide F 63 Anticalins R 63 CA9 SCAN 63 epigenetic therapies 63 indibulin 62 HuMax EGFr 62 vivo preclinical 62 LHRH receptor positive 62 Spiegelmer 62 Pertuzumab 62 acadesine 62 Smac mimetics 62 PPARγ 62 generation purine nucleoside 62 ALK inhibitors 62 farletuzumab 62 PDE4 inhibitor 62 Davanat 62 AKT inhibitor 62 HSP# inhibitor 62 MEK inhibitors 62 radiotherapeutic 62 TLR agonists 62 flavopiridol 62 cilengitide 62 YONDELIS R 62 synthetic retinoid 62 orally bioavailable 62 Zybrestat 62 oral antiviral 62 thalidomide Thalomid 62 dasatinib Sprycel 62 human IgG1 monoclonal 62 DepoVax ™ 62 sorafenib Nexavar 62 targeted antifolate 62 Cancidas 61 vascular disrupting agents 61 PSMA ADC 61 depsipeptide 61 gefitinib Iressa 61 humanized antibody 61 immunotherapeutic vaccine 61 Myolimus 61 Angiotensin Converting Enzyme 61 TRV# [001] 61 JAK inhibitors 61 NeuroVax 61 pharmacodynamic properties 61 anti fibrotic 61 IMA# 61 GW# [003] 61 Certolizumab pegol 61 THR beta agonist 61 HDL Selective Delipidation 61 Erimos 61 Modrenal 61 reslizumab 61 endothelin antagonist 61 potent cytotoxic 61 PrevOnco ™ 61 vivo validation 61 busulfan 61 Velcade bortezomib 61 ENMD # 61 antitumoral 61 oral prodrug 61 erythropoietic 61 OHR/AVR# 61 mertansine 61 CTAP# Capsules 61 radiolabeled TM# 61 CCR5 inhibitor 61 BEZ# 61 antimitotic 61 subcutaneous immunoglobulin 61 radiolabeled 61 ReN# 61 rxRNA 61 ospemifene 61 vidofludimus 61 PHX# 61 adult mesenchymal stem 61 2DG 61 Quinamed 61 TLR9 agonist 61 ChronVac C ® 61 rindopepimut 61 adipose derived stem cell 61 isoform selective 61 GRNVAC1 61 TransVax tm 60 Pim kinases 60 triphendiol 60 Afatinib 60 Vandetanib 60 JAK2 inhibitors 60 mecamylamine 60 Proellex TM 60 imexon 60 liposomal formulation 60 Interferon beta 60 volociximab 60 antiproliferative effects 60 prostanoid 60 diagnostic biomarker 60 aurora kinase 60 nanopharmaceutical 60 peptidomimetic 60 ESBA# 60 rBChE 60 ISF# 60 PET tracers 60 Bendamustine 60 Capsulution 60 NPC 1C 60 selective orally bioavailable 60 acyclovir Lauriad R 60 intratumoral injection 60 uricase 60 Canvaxin TM 60 receptor inhibitor 60 personalized dendritic 60 Tectin TM 60 GAMMAGARD 60 Aflibercept 60 Zysolin TM 60 preclinical pharmacology 60 non nucleoside 60 Neuradiab 60 OMP #M# 60 OvaRex R 60 AFFiRiS 60 BIM #A# 60 histone deacetylases 60 radioprotective 60 Pitavastatin 60 Valdoxan 60 Rasagiline 60 teriflunomide 60 novel therapeutic antibodies 60 Sorafenib Nexavar 60 anti CD3 60 concurrent chemoradiation 60 selective modulator 60 adenoviral 60 OvaRex MAb 60 TRIST study 60 Curaxin CBLC# 60 selective inhibition 60 XmAb# 60 telomerase therapeutic 60 ZOLINZA 60 preclinical efficacy 60 Teysuno 60 CRLX# 60 humanized monoclonal antibodies 60 recombinant antibodies 60 immuno modulatory 60 Resten MP 60 immunoconjugate 60 fulvestrant 60 Pemetrexed 60 SUTENT ® 60 Hedgehog inhibitor 60 lipopeptide 60 CINQUIL 60 docetaxel Taxotere ® 60 AMPK activators 60 Curaxin 60 VitiGam 60 erlotinib Tarceva ® 60 A3 adenosine receptor 60 lapatinib Tykerb 60 SIR Spheres 60 huN# DM1 60 Lixivaptan 60 allogeneic cell 60 insulin sensitizing 59 Poly ICLC 59 Azacitidine 59 MorphoSys proprietary 59 TransMID 59 Janus Kinase 59 Capesaris 59 miglustat 59 ATIR 59 JAK inhibitor 59 anti secretory 59 vorinostat 59 Apo2L 59 SERMs 59 receptor tyrosine kinase inhibitor 59 immunomodulation 59 multitargeted 59 mda 7 59 anticancer activity 59 Aviptadil 59 monoclonal anti 59 NOD SCID mice 59 ChronVac C R 59 predictive toxicology 59 haematological cancers 59 multicenter Phase II 59 Belldegrun 59 antitumor effect 59 pertuzumab 59 nicotinic receptor 59 NEUGENE 59 Micromet BiTE 59 Zevalin consolidation 59 DXL# 59 hapten 59 tyrosine kinase inhibitor 59 chimeric monoclonal antibody 59 antiangiogenic 59 Panzem R NCD 59 OncoGel 59 demonstrated antitumor activity 59 theranostic 59 SNS# T 59 pramlintide metreleptin combination 59 GeneICE 59 Annamycin 59 radiolabeled monoclonal antibody 59 tumorigenicity 59 anti angiogenic drugs 59 SYN# 59 TASKi3 59 humanized monoclonal 59 regorafenib 59 Allovectin 7 ® 59 Anavex #-# 59 Symadex 59 Elvitegravir 59 immunoregulatory 59 bispecific antibody 59 Factor VIIa 59 GelSite R polymer 59 EP #R 59 Intravail ® 59 radioimmunotherapy RIT 59 inhibitor RG# 59 hypomethylating agent 59 CCX# 59 intravesical instillation 59 biomarker assays 59 cellular immunotherapy 59 bardoxolone 59 Preclinical studies suggest 59 nucleotide analogue 59 Pharmacokinetic studies 59 Liposomal 59 ActA 59 chemopreventive agents 59 PARP inhibitor 59 Anticalins ® 59 Multimeric 59 Vascugel R 59 molecularly targeted therapy 59 PORxin TM 59 antiangiogenic therapy 59 cediranib 59 Sphingomab 59 eligen 59 Angiocept 59 targeting PCSK9 59 telomerase activator 59 transduced cells 59 DepoVax TM 59 GLP toxicology studies 59 antisense inhibitors 59 pharmacokinetic pharmacodynamic 59 RNA antagonists 59 Silodosin 59 PEG SN# 59 inhibit metastasis 59 PrevOnco 59 ZD# [001] 59 oral antiplatelet agent 59 trastuzumab DM1 T DM1 59 anti angiogenic agents 59 Traficet EN 59 DCCR 59 GRN# 59 therapeutic monoclonal antibodies 59 Cyclosporin 59 lymphoid malignancies 59 Bayer HealthCare Onyx Pharmaceuticals 59 Daclizumab 59 urothelial bladder cancer 59 TLK# 59 ImmuKnow R 59 IMiDs ® 59 eniluracil 59 GMX# 58 TLR8 58 Novolimus 58 MGd 58 RezularTM 58 EOquin TM phase 58 antitumour 58 protein tyrosine kinase 58 Factor Xa inhibitor 58 histone deacetylase HDAC inhibitors 58 IgG1 antibody 58 anti CD3 antibody 58 anticancer therapeutics 58 TAKSTA 58 murine models 58 abacavir Ziagen 58 HuLuc# 58 thetreatment 58 gemtuzumab ozogamicin 58 fosbretabulin 58 Marqibo TM 58 tranilast 58 Selective Electrochemical Tumor Ablation 58 eTag assays 58 targeted radiotherapeutic 58 radezolid 58 poly ADP ribose polymerase 58 DNA methyltransferases 58 Hemopurifier ® 58 CYT# potent vascular disrupting 58 immatics 58 IGF 1R inhibitor 58 Triapine 58 neuro protective 58 HDACi 58 EGFR TKIs 58 Talotrexin 58 Phase IIb clinical trials 58 metastatic colorectal 58 Teplizumab 58 GPR# agonists 58 Arranon 58 siRNA therapeutic 58 PSN# [001] 58 mGluR5 antagonist 58 Neuradiab TM 58 BCR ABL inhibitor 58 Campath alemtuzumab 58 Degarelix 58 alefacept 58 bispecific 58 Dr. Sosne 58 unresectable tumors 58 morpholino 58 splice variants 58 intranasal delivery 58 Dalbavancin 58 Nanobody R 58 prostate carcinoma 58 HSP# inhibitors 58 immune stimulatory 58 iron chelators 58 Cx# [002] 58 urothelial cancer 58 romazarit 58 enzyme inhibitor 58 olaparib 58 Accium 58 successfully commercialize Iluvien 58 Tyrima 58 visilizumab 58 histone deacetylase inhibitors 58 HuMax CD4 58 Vidaza azacitidine 58 clevidipine 58 peptide antigens 58 transfection reagent 58 synthetic lethality 58 Kamada AAT 58 telomerase inhibitor 58 Omacetaxine 58 mTOR inhibitor 58 prognostic biomarker 58 neuronal nicotinic receptor NNR 58 DEB# 58 eprotirome 58 receptor blocker 58 potent antiproliferative 58 RH1 58 ONCONASE R 58 Nexavar sorafenib 58 Scancell 58 proprietary PEGylation 58 gemcitabine carboplatin 58 humanized mouse 58 Teriflunomide 58 antiangiogenic agent 58 pharmacodynamic PD 58 colorectal liver metastases 58 targeting CD# 58 vinca alkaloid 58 ghrelin antagonist 58 monoclonal antibody MAb 58 RhuDex ® 58 PDE# inhibitors 58 relapsed MM 58 FVIIa 58 GVAX ® 58 Sudhir Agrawal D.Phil 58 adenoviral vectors 58 highly immunogenic 58 cathepsins 58 GHRH 58 Chipscreen 58 Affimed 58 Bacillus Calmette Guerin BCG 58 antituberculosis 58 Anticalins 58 Lisofylline 58 Interferon alpha 58 immunotherapeutic approaches 58 pancreatic adenocarcinoma 58 juvenile chondrocytes 58 potentiator 58 vivo potency 58 pain palliation 58 Phase #b/#a clinical 58 kinase inhibition 58 refractory CLL 58 Eniluracil 58 epothilones 58 ASONEP 58 Tyrosine Kinase Inhibitor 58 oxazolidinone 58 cytoreductive nephrectomy 58 personalized immunotherapy 58 TriGrid 58 Deforolimus 58 accumulate preferentially 58 Alpha lipoic acid 58 OncoVEX 58 vinblastine 58 neuronal nicotinic receptors NNRs 58 pharmacogenetic testing 58 StemEx R 58 ADME properties 58 mTOR inhibition 58 NEUGENE antisense 58 LEAPS TM 58 liposomal delivery 58 novel immunotherapeutic 58 antitumor 58 trastuzumab Herceptin 58 Ophena 58 A2A receptor 58 microRNA profiling 58 CB1 antagonists 58 Phe restricted diet 58 rhITF 58 maximally tolerated dose 58 PKCi 57 cetuximab Erbitux R 57 DepoVax 57 PORxin 57 bevacizumab Avastin ® 57 vemurafenib 57 druggable target 57 BGC# 57 enzyme inhibitors 57 hESC derived cardiomyocytes 57 epoetin alpha 57 membranous nephropathy 57 vascular thrombosis 57 antiproliferative activity 57 Inhaled nitric oxide 57 Ontak 57 caspofungin 57 HuMax 57 druggable 57 iPS derived 57 optimal dosing 57 BrachySil 57 favorable pharmacokinetic profile 57 Simulect 57 antiangiogenesis 57 erlotinib Tarceva 57 Pancreate 57 tremelimumab 57 Neuvenge 57 antiapoptotic 57 direct thrombin inhibitors 57 blood clot dissolving 57 HepDirect 57 lipid nanoparticle 57 validate biomarkers 57 p# biomarker 57 anticoagulant reversing agent 57 IIa trials 57 topically administered 57 PEGPH# 57 antiresorptive 57 ImmunoGen TAP technology 57 Fc fusion protein 57 IL# PE#QQR 57 LHRH 57 lyophilized formulation 57 novel oral anticoagulant 57 pharmacokinetic PK study 57 Surgical resection 57 Melphalan 57 Vidofludimus 57 lenalidomide Revlimid R 57 Enkephalin 57 M1 muscarinic 57 OncoVEX GM CSF 57 CDK inhibitor 57 administered intranasally 57 immunotoxins 57 radiotherapy RT 57 metastatic neuroendocrine tumors 57 phase IIIb 57 MAGE A3 ASCI 57 Corgentin 57 receptor antagonism 57 synthetic peptide containing 57 MyVax ® 57 paclitaxel Taxol R 57 drug conjugate 57 factor Xa inhibitor 57 Vascugel ® 57 Copegus ribavirin 57 nicotinic acetylcholine receptor 57 Euroscreen 57 selectively inhibiting 57 Cloretazine 57 DCVax ® 57 Azedra 57 Immunohistochemical analysis 57 inverse agonist 57 tumor vascular disrupting 57 Dasatinib 57 mg kg BID 57 liposomal amphotericin B 57 syngeneic 57 Islet transplantation 57 DU #b 57 JAK1 57 AERx iDMS 57 ibudilast 57 pro angiogenic 57 liposomal doxorubicin 57 malignant ascites 57 Anticalin 57 dose melphalan 57 PKC# 57 Affimed Therapeutics AG 57 octreotide implant 57 zinc finger nucleases 57 GIPET 57 selective adenosine 57 Pagoclone 57 Phase Ib study 57 Panzem NCD 57 small molecule modulators 57 riociguat 57 PK PD 57 Novosom 57 IGF IR 57 transgenic mouse models 57 selective inhibitors 57 tiapamil 57 blood clot dissolver 57 Myocet 57 Cethrin R 57 antisense drug 57 intranasal formulation 57 AdhTAP 57 ZACTIMA 57 samalizumab 57 Apatone 57 cisplatin resistant 57 colon carcinoma 57 Trofex 57 nonsmall cell lung cancer 57 Cellcept 57 partial agonists 57 ER CHOP 57 Axiogenesis 57 subcutaneous SC 57 biologic therapeutics 57 Cand5 57 Caris MPI 57 Aptivus ® 57 HyACT 57 HER2 positive metastatic breast 57 retaspimycin 57 ancrod 57 macrolide antibiotics 57 calcitonin gene related 57 investigational therapies 57 AAV vector 57 CG# [003] 57 oral PTH 57 SERCA2a 57 trabectedin 57 BioMarck 57 Aggrastat ® tirofiban hydrochloride 57 prodrugs 57 tumor subtypes 57 HYC# 57 molecularly targeted 57 corticosteroid dexamethasone 57 vivo pharmacology 57 HPCGG 57 cellular cytotoxicity 57 cinacalcet 57 Telatinib 57 kidney urologic 57 clinically tested 57 Inosine 57 retinoid X 57 Allovectin 7 57 immune modulatory 57 DCVax 57 siRNA therapeutics 57 GAP #B# 57 RE LY trial 57 USP# 57 leflunomide 57 bladder carcinoma 57 potent anticancer 57 pegylated alpha interferon 57 TNFerade TM 57 TaiGen 57 XenoTech 57 etanercept Enbrel 57 gastrointestinal stromal tumors GISTs 57 Abiraterone 57 lysophosphatidic acid 57 Gleevec resistant 57 midstage clinical 57 letrozole Femara 57 CIMZIA ™ 57 neoadjuvant setting 57 NTDDS 57 convenient dosing regimens 57 Ostabolin C TM 57 lentiviral 57 HuCNS SC ® 57 Aethlon Hemopurifier R 57 Cdc7 57 pharmacokinetic PK profile 56 siRNA transfection 56 triterpenoids 56 Bioral Amphotericin B 56 biomarker identification 56 somatostatin analogue 56 murine monoclonal antibody 56 LCP Tacro TM 56 peripherally acting 56 Phase IIb III 56 galiximab 56 OvaRex ® MAb 56 gemcitabine Gemzar ® 56 gemcitabine cisplatin 56 conformal radiotherapy 56 MabThera rituximab 56 EC Cysteamine 56 HBV vaccine 56 human microdosing 56 metastatic gastric 56 Syk 56 cytoprotective 56 PDGF receptor 56 Nanobody ® 56 Ophena TM 56 mechanistic studies 56 immune modulator 56 immunotherapy treatments 56 Elotuzumab 56 MYDICAR ® 56 Litx 56 neuroprotective properties 56 Posiphen TM 56 multiple myeloma MM 56 Myelodysplastic Syndrome MDS 56 OGeS 56 Illumina Solexa 56 imatinib Gleevec 56 protein receptors lectins 56 DermaVir Patch 56 DPX Survivac 56 Onconova 56 Gemzar gemcitabine 56 Spiegelmers R 56 GLYX 56 antitumor effects 56 Estrogen Receptor 56 HDL Mimetic Peptide 56 Anti VEGF 56 autologous transplant 56 imatinib therapy 56 NSABP B 56 albumin bound paclitaxel 56 NP2 Enkephalin 56 predictive biomarker 56 ara C 56 OvaRex 56 Tarvacin TM 56 Phase #b/#a trial 56 Vaccinex 56 TKM PLK1 56 MabCampath 56 peritoneal carcinomatosis 56 fusion enhancers 56 inactivating mutations 56 Her2/neu 56 mutated K ras 56 GERD migraine headaches 56 investigational HCV polymerase 56 demethylating agent 56 bone marrow progenitor cells 56 chemoresistant 56 geldanamycin 56 commercialize deforolimus 56 DP b# 56 TNF alpha inhibitor 56 candidate deforolimus 56 recombinant enzyme 56 BRAF V#E mutation 56 Phage Pharmaceuticals 56 VersaFilm 56 adipose derived stem cells 56 papillary renal cell carcinoma 56 Protagen 56 sodium glucose transporter 56 pediatric malignancies 56 Irinotecan 56 refractory prostate cancer 56 MAb 56 prostacyclins 56 TMEM#B 56 Gefitinib 56 Amplimexon 56 binds selectively 56 pDCs 56 Enzyme Replacement Therapy 56 initiate Phase 2b 56 Thiovir 56 rituximab Rituxan 56 Revimmune 56 trastuzumab Herceptin ® 56 Pyridorin 56 PEG IFN 56 Ceflatonin 56 MediVas 56 sd rxRNA 56 molecular biomarkers 56 miRNA biomarkers 56 interferon lozenges 56 panobinostat 56 Oncotype 56 p# inhibitor 56 deforolimus 56 NanoCrystal technology 56 kallikrein 56 maturation inhibitors 56 Cylene 56 denileukin diftitox 56 pafuramidine maleate 56 ToleroMune 56 maximally tolerated lipid lowering 56 neuroactive 56 liposome formulation 56 Fludara ® 56 UPLYSO 56 novel radiopharmaceuticals 56 Antiangiogenic 56 aerosolized KL4 surfactant 56 hypoxic tumors 56 TBC# 56 goserelin 56 Anticalin R 56 MyVax 56 viral kinetics 56 cyclophilin inhibitors 56 hepatitis C viral infection 56 HepDirect technology 56 mTOR inhibitors 56 AMPAKINE 56 metastatic bladder 56 NITD# 56 metastatic malignant 56 PCA3 assay 56 optimal dosing regimens 56 monoclonal antibody mAb 56 relapsed ALL 56 Urocortin 2 56 imatinib mesylate Gleevec 56 BioSET 56 ATL# [002] 56 FOSRENOL ® 56 Pazopanib 56 clinically differentiated 56 chimeric protein 56 potent inducer 56 efficacy endpoint 56 pegylated liposomal doxorubicin 56 verteporfin 56 TG# [003] 56 anti tumoral 56 xenograft models 56 monoclonal antibody conjugated 56 including eniluracil ADH 56 chemoradiotherapy 56 histone deacetylase HDAC 56 Glypromate 56 lenalidomide Revlimid 56 CCR9 antagonist 56 Anticalin ® 56 PhG alpha 1 56 Cloretazine ® 56 Bioral 56 Surfaxin LS 56 VIBEX MTX 56 ibritumomab tiuxetan 56 receptor modulators 56 Therapeutic antibodies 56 colorectal cancer liver metastases 56 acetonide FA 56 Diasome 56 Multiferon ® 56 oral ghrelin agonist 56 Diamyd ® 56 metabolomic profiles 56 StemEx 56 ocular disorders 56 Zavesca r 56 myeloproliferative disorders 56 cMET 56 Interferon alfa 56 metabolite identification 56 ganciclovir 56 Bellicum 56 prokinetic 56 inhibit viral replication 56 metabolite profiling 56 Pralatrexate 56 DCVax R 56 CVac 56 HuMax TAC 56 metabonomics 56 Inflammatory diseases 56 Kinoid 56 antiproliferative 56 radionuclide therapy 56 superficial bladder cancer 56 Tocilizumab 56 rALLy trial 56 tumor immunology 56 infliximab Remicade 56 LymphoStat B belimumab 56 SNT MC# 56 intravenous immunoglobulin 56 somatostatin analog 56 paricalcitol 56 Immunotherapeutic 56 Transcranial Magnetic Stimulation TMS 56 nasal formulation 56 bioresorbable stent 56 UsiRNAs 56 N acetylcysteine 56 novel anticancer 56 relapsed leukemia 56 Wnt signaling pathway 56 RRM1 56 antidiabetic drugs 56 recurrent glioblastoma multiforme 56 IGFBP2 56 NADiA 56 Kantarjian 56 intra arterial chemotherapy 56 immunotherapeutics 56 masitinib 56 pan HDAC inhibitor 56 thymosin 56 metastatic malignant melanoma 56 immunomodulatory agents 56 BCR ABL inhibitors 56 cytotoxic T lymphocyte 56 iPSC 56 Combidex 56 cyclic peptide 56 Mycophenolate Mofetil 56 carbohydrate polymer 56 Aeroquin 56 regenerative biology 56 Hsp# inhibition 56 Dr. Pestell 56 Virulizin 56 cortical stimulation 56 paclitaxel poliglumex 56 acetylcholinesterase AChE 55 APTIVUS 55 milatuzumab 55 urate oxidase 55 Oral NKTR 55 multikinase inhibitor 55 vitro dissolution 55 angiogenesis inhibition 55 inecalcitol 55 temozolomide TMZ 55 Locked Nucleic Acid LNA 55 KL4 surfactant 55 Zalypsis 55 mimetic compounds 55 chemopreventive 55 cysteamine bitartrate 55 protein tyrosine 55 Vaxfectin TM 55 Cerashield 55 Zacharon 55 ixabepilone 55 chemotherapeutic drugs 55 immunological diseases 55 neuroregenerative 55 mimetics 55 Nanobody 55 Teriparatide 55 administered intraperitoneally 55 tocilizumab 55 eribulin mesylate 55 bioengineered tissue 55 Fabry Disease 55 BrachySil ™ 55 nonsteroidal 55 hypoxia activated prodrug 55 GPCR targets 55 TransMID TM 55 HepaGam B 55 heparins 55 lung fibrosis 55 G#DT 55 Foradil Aerolizer 55 biased ligand 55 nonviral 55 relapsed ovarian cancer 55 systemic RNAi 55 Sodroski 55 DCVax ® Brain 55 basal bolus regimen 55 adenosine A2A 55 Xelox 55 budesonide MMX Phase III 55 Novacta 55 IV Busulfex 55 Mepact 55 anagrelide 55 Enhanze Technology 55 PEGylated 55 lymphomas leukemias 55 Anthim 55 interferon lambda 55 Kinase Inhibitor 55 EOquin TM 55 MDS AML 55 differentiated thyroid 55 MMP inhibitors 55 orally disintegrating 55 potency selectivity 55 Intravenous immunoglobulin 55 vitro cytotoxicity 55 prostate cancer PCa